Hims & Hers Takes Advantage of Novo's Blunder: Entry with Generic Semaglutide in Canada

Rare Oversight with Signal Effect: Novo Nordisk loses the Semaglutide patent in Canada – Hims & Hers seizes the gap for market entry. A Form Error with Billion-Dollar Impact: By missing the patent extension, Novo opens the door for Hims & Hers to access the Canadian weight loss market. A missed paperwork opportunity with significant consequences: Because Novo Nordisk stopped paying the maintenance fees for its Semaglutide patent in Canada, the patent protection for the active ingredient in the weight loss injections Ozempic and...